Cardiomyopathie cirrhotique : une entité spécifique

Haute Autorité de santé. Surveillance des malades atteints de cirrhose non compliquée et prévention primaire des complications. HAS, 2007. Sawadogo, 2007, Physiopathologie de la cirrhose et de ses complications, Reanimation, 16, 557, 10.1016/j.reaurg.2007.09.001 Møller, 2008, Cardiovascular complications of cirrhosis, Gut, 57, 268, 10.1136/gut.2006.112177 Ruiz-del-Arbol, 2005, Circulatory function and hepatorenal syndrome in cirrhosis, Hepatology, 42, 439, 10.1002/hep.20766 Mandell, 2008, Cardiovascular dysfunction in patients with end-stage liver disease, J Chin Med Assoc, 71, 331, 10.1016/S1726-4901(08)70134-5 Møller, 2002, Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease, Heart, 87, 9, 10.1136/heart.87.1.9 Arroyo, 2002, Pathophysiology, diagnosis and treatment of ascites in cirrhosis, Ann Hepatol, 1, 72, 10.1016/S1665-2681(19)32178-7 Wong, 1999, Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis, Clin Sci (Lond), 97, 259, 10.1042/cs0970259 Henriksen, 2002, Review article: volume expansion in patients with cirrhosis, Aliment Pharmacol Ther, 16, 12, 10.1046/j.1365-2036.16.s5.3.x Lotterer, 1999, Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis, Hepatology, 29, 632, 10.1002/hep.510290302 Linas, 1986, Peritoneovenous shunt in the management of the hepatorenal syndrome, Kidney Int, 30, 736, 10.1038/ki.1986.249 Pozzi, 2006, Cardiovascular abnormalities in special conditions of advanced cirrhosis. The circulatory adaptative changes to specific therapeutic procedures for the management of refractory ascites, Gastroenterol Hepatol, 29, 263, 10.1157/13086820 Limas, 1974, Impaired left ventricular function in alcoholic cirrhosis with ascites: ineffectiveness of ouabain, Circulation, 49, 755, 10.1161/01.CIR.49.4.755 Therapondos, 2004, Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study, J Gastroenterol Hepatol, 19, 73, 10.1111/j.1440-1746.2004.03226.x McCormick, 1995, Cardiovascular effects of octreotide in patients with hepatic cirrhosis, Hepatology, 21, 1255, 10.1002/hep.1840210507 Mikulic, 1983, Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis, Clin Pharmacol Ther, 34, 56, 10.1038/clpt.1983.129 Lunzer, 1975, Impaired cardiovascular responsiveness in liver disease, Lancet, 2, 382, 10.1016/S0140-6736(75)92896-2 Ramond, 1986, Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity, Br J Clin Pharmacol, 21, 191, 10.1111/j.1365-2125.1986.tb05174.x Laffi, 1997, Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis, Gastroenterology, 113, 891, 10.1016/S0016-5085(97)70184-7 Wong, 2001, The cardiac response to exercise in cirrhosis, Gut, 49, 268, 10.1136/gut.49.2.268 Lee, 1988, Postprandial hemodynamic responses in patients with cirrhosis, Hepatology, 8, 647, 10.1002/hep.1840080335 Lee, 1989, Cardiac abnormalities in liver cirrhosis, West J Med, 151, 530 Baik, 2007, Cirrhotic cardiomyopathy, Orphanet J Rare Dis, 2, 15, 10.1186/1750-1172-2-15 Valeriano, 2000, Modification of cardiac function in cirrhotic patients with and without ascites, Am J Gastroenterol, 95, 3200, 10.1111/j.1572-0241.2000.03252.x Finucci, 1996, Left ventricular diastolic function in liver cirrhosis, Scand J Gastroenterol, 31, 279, 10.3109/00365529609004879 Pozzi, 1997, Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites, Hepatology, 26, 1131 Torregrosa, 2005, Cardiac alterations in cirrhosis: reversibility after liver transplantation, J Hepatol, 42, 68, 10.1016/j.jhep.2004.09.008 Ma, 1996, Cirrhotic cardiomyopathy: getting to the heart of the matter, Hepatology, 24, 451, 10.1002/hep.510240226 Pirat, 2005, Right ventricular systolic function is supernormal in patients with cirrhosis, Eur J Echocardiography, 6 Suppl., S21 Zambruni, 2006, Cardiac electrophysiological abnormalities in patients with cirrhosis, J Hepatol, 44, 994, 10.1016/j.jhep.2005.10.034 Hansen, 2007, Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes, J Hepatol, 47, 373, 10.1016/j.jhep.2007.03.013 Bernardi, 1998, Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors, Hepatology, 27, 28, 10.1002/hep.510270106 Henriksen, 2002, Dyssynchronous electrical and mechanical systole in patients with cirrhosis, J Hepatol, 36, 513, 10.1016/S0168-8278(02)00010-7 Mohamed, 1996, Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease, Hepatology, 23, 1128, 10.1002/hep.510230529 Zambruni, 2007, QT interval correction in patients with cirrhosis, J Cardiovasc Electrophysiol, 18, 77, 10.1111/j.1540-8167.2006.00622.x Schouten, 1991, QT interval prolongation predicts cardiovascular mortality in an apparently healthy population, Circulation, 84, 1516, 10.1161/01.CIR.84.4.1516 Kelly, 1980, Vasopressin provocation of ventricular dysrhythmia, Ann Intern Med, 92, 205, 10.7326/0003-4819-92-2-205 Eden, 1983, Ventricular arrhythmia induced by vasopressin : torsade de pointes related to vasopressin-induced bradycardia, Mt Sinai J Med, 50, 49 Nakasone, 2001, Alcoholic liver cirrhosis complicated with torsade de pointes during plasma exchange and hemodiafiltration, J Gastroenterol, 36, 564, 10.1007/s005350170061 Zambruni, 2008, Acute gastrointestinal bleeding prolongs QT interval in cirrhosis, Dig Liver Dis, 40, A1, 10.1016/j.dld.2007.12.084 Mandell, 2008, Cardiac evaluation of liver transplant candidates, World J Gastroenterol, 14, 3445, 10.3748/wjg.14.3445 Mark, 2004, B-type natriuretic peptide–A biomarker for all seasons?, N Engl J Med, 350, 718, 10.1056/NEJMe038233 Henriksen, 2003, Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease, Gut, 52, 1511, 10.1136/gut.52.10.1511 Iwao, 2000, High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis, J Hepatol, 32, 426, 10.1016/S0168-8278(00)80393-1 Pateron, 1999, Elevated circulating cardiac troponin I in patients with cirrhosis, Hepatology, 29, 640, 10.1002/hep.510290332 Ma, 1997, Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy, J Hepatol, 26, 904, 10.1016/S0168-8278(97)80259-0 Ward, 1997, Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis, Am J Physiol, 273, G537 Therapondos, 2004, Cardiac morbidity and mortality related to orthotopic liver transplantation, Liver Transpl, 10, 1441, 10.1002/lt.20298 Al Hamoudi, 2006, Cirrhotic cardiomyopathy, Ann Hepatol, 5, 132, 10.1016/S1665-2681(19)31996-9 Lee, 2007, Cardiac dysfunction in cirrhosis, Best Pract Res Clin Gastroenterol, 21, 125, 10.1016/j.bpg.2006.06.003